Evidence map›Paper›PMID 39922894›Full record

ArticleScientific reports2025

Looking outside the box with a pathology aware AI approach for analyzing OCT retinal images in Stargardt disease.

Parisa Khateri, Tiana Koottungal, Damon Wong, Rupert W Strauss, Lucas Janeschitz-Kriegl, Maximilian Pfau, Leopold Schmetterer, Hendrik P N Scholl

Abstract read
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Parisa KhateriInstitute of Molecular and Clinical Ophthalmology Basel, Basel, Switzerland. parisa.khateri@gmail.com.
Tiana KoottungalInstitute of Molecular and Clinical Ophthalmology Basel, Basel, Switzerland.
Damon WongInstitute of Molecular and Clinical Ophthalmology Basel, Basel, Switzerland.
Rupert W StraussInstitute of Molecular and Clinical Ophthalmology Basel, Basel, Switzerland.
Lucas Janeschitz-KrieglInstitute of Molecular and Clinical Ophthalmology Basel, Basel, Switzerland.
Maximilian PfauDepartment of Ophthalmology, University of Basel, Basel, Switzerland.
Leopold SchmettererInstitute of Molecular and Clinical Ophthalmology Basel, Basel, Switzerland. leopold.schmetterer@seri.com.sg.
Hendrik P N SchollDepartment of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria. hpn.scholl@gmail.com.

Funding

Agency for Science, Technology and Research A20H4b0141Duke-NUS Medical School (05/FY2022/EX/66-A128; Duke-NUS-KBrFA/2024/0088Foundation Fighting Blindness Clinical Research Institute ProgStarNational Center of Competence in Research Molecular Systems Engineering 51NF40-182895National Health Innovation Centre Singapore NHIC-I2D-2402329National Medical Research Council OFLCG/004c/2018-00; MOH-000249-00; MOH-000500-00; MOH-000647-00; MOH-000707-00; MOH-001001-00; MOH-001015-00; MOH-001072-06; MOH-001286-00; MOH-001574-02; MOH-001576-00National Research Foundation Singapore NRF2019-THE002-0006; NRF-CRP24-2020-0001NIAID NIH HHS L30 AI172024NIAID NIH HHS L40 AI172024Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung 310030_201165Singapore Eye Research Institute I010/2024 [2082/44/2024]Singapore Eye Research Institute & Nanyang Technological University SERI-NTU Advanced Ocular Engineering (STANCE) ProgramSingHealth Foundation AM/TP085/2024 [SRDUKAMR2485); AM/AIR017/2024 [SRDUKAMR24A7]Wellcome TrustWellcome Trust PINNACLE
6 · The paper itself

Abstract

Stargardt disease type 1 (STGD1) is a genetic disorder that leads to progressive vision loss, with no approved treatments currently available. The development of effective therapies faces the challenge of identifying appropriate outcome measures that accurately reflect treatment benefits. Optical Coherence Tomography (OCT) provides high-resolution retinal images, serving as a valuable tool for deriving potential outcome measures, such as retinal thickness. However, automated segmentation of OCT images, particularly in regions disrupted by degeneration, remains complex. In this study, we propose a deep learning-based approach that incorporates a pathology-aware loss function to segment retinal sublayers in OCT images from patients with STGD1. This method targets relatively unaffected regions for sublayer segmentation, ensuring accurate boundary delineation in areas with minimal disruption. In severely affected regions, identified by a box detection model, the total retina is segmented as a single layer to avoid errors. Our model significantly outperforms standard models, achieving an average Dice coefficient of [Formula: see text] for total retina and [Formula: see text] for retinal sublayers. The most substantial improvement was in the segmentation of the photoreceptor inner segment, with Dice coefficient increasing by [Formula: see text]. This approach provides a balance between granularity and reliability, making it suitable for clinical application in tracking disease progression and evaluating therapeutic efficacy.

Indexed as

Image Processing, Computer-AssistedRetinaStargardt DiseaseTomography, Optical CoherenceAdultDeep LearningFemaleHumansMaleAutomated Image AnalysisDeep LearningOptical Coherence TomographyPathology-Aware Loss FunctionRetina SegmentationStargardt Disease

Identifiers

PMID39922894
PMCPMC11807158

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.